Navigation Links
Hanger Reports Second Quarter 2013 Results

AUSTIN, Texas, July 31, 2013 /PRNewswire/ --

  • Reports adjusted diluted EPS of $0.52
  • Reports $0.40 diluted EPS
  • Achieves same center sales growth of 3.9%
  • Raises annual adjusted EPS guidance to range of $2.07-$2.13 to reflect the combined impact of debt refinancing and increased costs
  • Hanger, Inc. (NYSE: HGR) announced net sales of $273.7 million for the quarter ended June 30, 2013, an increase of $22.0 million, or 8.7%, from $251.7 million for the second quarter of 2012.
    Diluted earnings per share were $0.40 for the second quarter of 2013 compared to $0.50 for the same period of 2012.  Adjusted diluted earnings per share, which excludes costs related to acquisitions, implementation of the Company's new clinic management system (which the Company refers to as "Janus"), and debt issuance cost associated with the June 2013 refinancing of the Company's bank credit facilities, increased 2% to $0.52 for the second quarter of 2013 from $0.51 for the second quarter of 2012.

    "We are pleased with our overall sales performance in the quarter despite a difficult macro environment, but are not satisfied with our second quarter earnings," commented Vinit K. Asar, President and Chief Executive Officer of Hanger. "Same center sales in our Patient Care segment continued to be strong, delivering 3.9% growth in the quarter.  However, higher costs in the quarter related to increased Recovery Audit Contractor (RAC) audits, sequestration and employee benefits had a negative impact on operating margin of approximately 100 basis points compared to Q2 last year.  During the second half of 2013 we will remain sharply focused on the key value drivers of our business - same center sales and O&P acquisitions - while we weather regulatory pressures and cost increases with an increasing focus on reducing material costs and driving other efficiency initiatives."

    The second quarter net sales increase of $22.0 million, or 8.7%, was the result of a $23.1 million, or 11.1%, increase in the Patient Care segment, partially offset by a $1.1 million, or 2.6%, decrease in the Products & Services segment. The $23.1 million increase in Patient Care segment sales was comprised of an $8.1 million, or 3.9%, increase in same center sales, with the remaining $15.0 million increase driven primarily by acquisitions closed in the prior year. The 2.6% decline in the Products & Services segment sales was a result of lower sales from the Company's distribution business, SPS, partially offset by a mid-single-digit increase in sales from its rehabilitative solutions business, ACP. The decline in sales at the distribution business was principally the result of the impact on SPS's customer base of the acquisitions of independent O&P companies made by the Patient Care segment in 2012, and a decline in demand for higher priced prosthetic devices (such as micro processor-controlled knees) from independent O&P practices due to pressure they are facing from RAC audits.

    Income from operations for the quarter ended June 30, 2013 was $36.6 million, compared to $35.7 million in the prior year.  Adjusted income from operations for the second quarter, which excludes costs related to acquisitions and the implementation of Janus, was $37.0 million, compared to $36.1 million in the prior year.  Adjusted income from operations as a percentage of revenue was 13.5% for the second quarter of 2013, which is a 0.8% decrease compared to the same period in 2012.  The principal reasons for the decrease in operating margins were the impact of sequestration, increased employee benefit costs and the impact of RAC audits on our Patient Care segment.

    Net sales for the six months ended June 30, 2013 increased $37.4 million, or 8.0%, to $507.3 million from $469.9 million in 2012.  The sales increase was driven by a $10.8 million, or 2.8%, increase in same-center sales in the Patient Care segment and a $28.8 million increase from acquired entities which were offset by a $2.4 million, or 2.8%, decrease in sales in the Products & Services segment.  Diluted earnings per share were $0.67 for the first six months of 2013 compared to $0.75 for the same period of 2012.  Adjusted diluted earnings per share, which excludes costs related to acquisitions, the implementation of Janus, and debt issuance cost associated with the June 2013 refinancing of the Company's bank credit facilities, increased 5% to $0.80 for the first six months of 2013 compared to adjusted diluted earnings per share of $0.76 for the first six months of 2012.

    The Company's cash flow from operations decreased slightly to $26.7 million for the six months ended June 30, 2013 compared to a $27.0 million cash inflow for the same period in 2012.  In June 2013, the Company refinanced its bank credit facilities through a new 5-year credit agreement that increased its senior secured facilities to an aggregate principal amount of up to $425 million. The new credit agreement includes a $200 million revolving credit facility and a $225 million term loan facility. As of June 30, 2013, the Company had $150.4 million in total liquidity, including $5.8 million of cash and $144.6 million available under its revolving credit facility, net of approximately $55.0 million of borrowings and $0.4 million in letters of credit.  The Company's leverage ratio, as defined in its credit facilities, remained steady at 2.8 times.

    The Company expects 2013 revenues of between $1.06 and $1.08 billion, which includes 3% to 5% same center sales growth in its Patient Care segment, and flat sales in its Products & Services segment. The Company increased its guidance for adjusted diluted earnings per share to a range of $2.07 to $2.13 for 2013, excluding costs related to the implementation of Janus of approximately $0.03, acquisition costs and debt issuance cost associated with the June 2013 refinancing of the Company's bank credit facilities.  This increased earnings guidance reflects lower interest expense related to the refinancing of the Company's bank credit facilities in June, partially offset by lower adjusted operating margin expansion for the year, which the Company believes will be in the range of 20 to 40 basis points. The Company anticipates generating cash flow from operations of between $80 million and $100 million in 2013 and investing a total of $40 million to $50 million in capital additions.  The Company will continue its acquisition program with a goal of closing acquisitions that total approximately $20 million in annualized revenues in 2013.

    A conference call to discuss these results is scheduled to begin at 9:00 a.m. Eastern, on Thursday, August 1, 2013. Those wishing to participate should call 1-877-662-6095. In addition, a replay will be available until midnight on Friday, August 9, 2013 by dialing 1-855-859-2056 and referencing Conference ID # 14811277.

    About Hanger, Inc. – Built on the legacy of James Edward Hanger, the first amputee of the American Civil War, Hanger, Inc. (NYSE: HGR) delivers orthotic and prosthetic (O&P) patient care, and distributes O&P products and rehabilitative solutions to the broader market.  Hanger's Patient Care segment is the largest owner and operator of O&P patient care clinics with in excess of 730 locations nationwide.  Through its Products & Services segment, Hanger distributes branded and private label O&P devices, products and components, and provides rehabilitative solutions.  Steeped in over 150 years of clinical excellence and innovation, Hanger's vision is to be the partner of choice for products and services that enhance human physical capability.  For more information on Hanger, visit and follow us at,, and

    This document contains forward-looking statements relating to the Company's results of operations.  The United States Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements.  Statements relating to future results of operations in this document reflect the current views of management.  However, various risks, uncertainties and contingencies could cause actual results or performance to differ materially from those expressed in, or implied by, these statements, including the Company's ability to enter into and derive benefits from managed care contracts, the demand for the Company's orthotic and prosthetic services and products, the impact of reviews, audits and investigations conducted from time to time by governmental agencies, and the other factors identified in Item 1A, "Risk Factors" in the Company's periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934.  The Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

     Hanger, Inc.(in thousands, except for share and per share amounts)(Unaudited)Three Months EndedSix Month EndedJune 30,June 30,Income Statement:2013201220132012Net sales

    469,845Material costs

    79,44672,899147,184139,597Personnel costs

    93,17683,435183,129164,588Other operating expenses

    54,78050,96698,55091,110Acquisition expenses

    179290252365Depreciation and amortization

    9,5108,43818,79516,723Income from operations

    36,64435,72659,36057,462Interest expense

    7,7087,68415,48515,461Extinguishment of debt

    6,645-6,645-Income before taxes

    22,29128,04237,23042,001Provision for income taxes

    8,21210,65613,66115,980Net income

    26,021Basic Per Common  Share Data:Net income

    .76Shares used to compute basic per share amounts

    34,849,65934,268,94134,724,07734,110,820Diluted Per Common Share Data:Net income 

    .75Shares used to compute diluted per share amounts

    35,307,69734,720,48935,225,87134,637,769Reconciliation of GAAP financial measures to Non-GAAP financial measures:Income from operations

    57,462Acquisition expenses

    179290252365Janus expenses

    2023758737Adjusted Income from operations

    57,864Net income 

    26,021Acquisition expenses

    179290252365Janus expenses

    2023758737Extinguishment of debt

    6,645-6,645-Tax effect of adjustments

    (2,586)(124)(2,747)(152)Adjusted net income 

    26,271Adjusted net income per diluted share

    .76Three Months EndedSix Month EndedJune 30,June 30,Income Statement as a % of Net Sales:2013201220132012Net sales

    100.0%100.0%100.0%100.0%Material costs

    29.0%29.0%29.0%29.7%Personnel costs

    34.0%33.1%36.1%35.0%Other operating expenses

    20.0%20.2%19.4%19.4%Acquisition expenses

    0.1%0.1%0.1%0.1%Depreciation and amortization

    3.5%3.4%3.7%3.6%Income from operations

    13.4%14.2%11.7%12.2%Interest expense

    2.8%3.1%3.1%3.3%Extinguishment of debt

    2.4%0.0%1.3%0.0%Income before taxes

    8.2%11.1%7.3%8.9%Provision for income taxes

    3.1%4.2%2.7%3.4%Net income 

    5.1%6.9%4.6%5.5%Adjusted income from operations

    13.5%14.3%11.9%12.3%Adjusted net income


     Hanger, Inc.( in thousands, except for statistical data)(Unaudited)Three Months EndedSix Months EndedJune 30,June 30,Cash Flow Data:2013201220132012Cash flow provided by operations 

    27,001Capital expenditures

    5,970Increase/(decrease) in cash and cash equivalents

    (1,283)Balance Sheet Data:June 30, 2013December 31, 2012Cash and cash equivalents$
    9,211Days Sales Outstanding (DSO's) *5958Working Capital $
    251,465Total Debt$
    520,646Shareholders' Equity$
    503,094*Excludes acquired accounts receivable balancesThree Months EndedSix Months EndedJune 30,June 30,2013201220132012Revenue Mix:Patient Care

    84.4%82.6%83.6%81.9%Products and Services

    15.6%17.4%16.4%18.1%Patient Care Payor Mix:Commercial and other




    6.2%6.0%6.2%6.0%Management relies on the non-GAAP items as the primary measures to review and assess operating performance and management teams. The Company believes it is useful to investors to provide disclosures of its operating results on the same basis as that used by management.  Management and investors also review the non-GAAP items to evaluate the Company's overall performance and to compare its current operating results with corresponding periods and with other companies in the health care industry. You should not consider the non-GAAP items in isolation or as a substitute for net income, operating cash flows or other cash flow statement data determined in accordance with accounting principles generally accepted in the United States. Because the non-GAAP items are not measures of financial performance under accounting principles generally accepted in the United States and are susceptible to varying calculations, they may not be comparable to similarly titled measures of other companies.  Adjusted net income, Adjusted income from operations, and Adjusted net income per diluted share are the non-GAAP financial measures.

    SOURCE Hanger, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Hanger clinicians honored with 2012 Tribeca Disruptive Innovation Award
    2. Hanger Orthopedic Group, Inc. announces name change to Hanger, Inc.
    3. Hanger, Inc. Announces Second Quarter 2012 Earnings Release Conference Call
    4. Hanger, Inc. Reports Earnings of $0.50 Per Diluted Share for the Second Quarter 2012
    5. Hanger, Inc. Announces 2012 Year To Date Acquisitions Totaling $35.6 Million Of Annual Net Revenue
    6. Hanger Reports Earnings of $0.50 Per Diluted Share for the Third Quarter 2012
    7. Hanger, Inc. Has Record Year In O&P Acquisitions:
    8. Hanger Reports $0.62 Diluted EPS for the Fourth Quarter 2012
    9. Hanger Files Form 10-K for Year Ended December 31, 2012
    10. Hanger, Inc. Announces First Quarter 2013 Earnings Release And Conference Call
    11. Hanger Reports First Quarter 2013 Results
    Post Your Comments:
    (Date:5/26/2016)... 2016 Since its commercial introduction ... essential life science tool for conducting genetic studies in ... reveals in its new report that the industry sits ... powered by a range of new applications in the ... ) , Since the ...
    (Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
    (Date:5/25/2016)... , May 25, 2016 As ... Expo earlier this month, the numbers and momentum of ... to climb into the billions, more research and development ... 4th Edition State of Legal Marijuana Markets Report  from ... data-analysis firm, much of the increase in sector is ...
    Breaking Medicine Technology:
    (Date:5/31/2016)... ... May 31, 2016 , ... Like jewels in a crown, the ... – London is home to Ontario’s leading day spa and one of Canada’s few ... began with a unique concept to combine spa services with hair and beauty ...
    (Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... WaterField Designs, ... digital-minded professionals, announces the waxed-canvas and leather Duo Dopp Kit , the ideal ... canvas or ballistic nylon, the Duo is smartly designed for Dad’s grooming ...
    (Date:5/31/2016)... , ... May 31, 2016 , ... Spectrum Aquatics has ... new lift has been designed and built with the user in mind. , “Over ... consultants have informed us that an ADA 400 lbs lift is a necessary requirement ...
    (Date:5/31/2016)... CA (PRWEB) , ... May 31, 2016 , ... Interest ... a primary screening tool and as an orthogonal tool for RNAi hit validation. A ... functional and specific guide RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in arrayed ...
    (Date:5/31/2016)... ... May 31, 2016 , ... TeaZa® Energy, LLC announces ... on World No Tobacco Day . The new flavor—Tropical TeaZa? Energy—will be ... this summer. , The new flavor is best described as a juicy, taste ...
    Breaking Medicine News(10 mins):